Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 130 | 169 | 69 | 202 | 84 |
| Gross Profit | 130 | 169 | 69 | 202 | 84 |
| Operating Expenses | 5,348 | 7,961 | 7,611 | 9,399 | 12,854 |
| Operating Income | -5,218 | -7,792 | -7,542 | -9,197 | -12,770 |
| Other Income | 262 | 366 | 1,795 | 594 | 760 |
| Pre-tax Income | -4,956 | -7,426 | -5,747 | -8,603 | -12,010 |
| Net Income Continuous | -4,960 | -7,426 | -5,747 | -8,603 | -12,014 |
| Net Income Discontinuous | 123 | 146 | -8 | -8 | -8 |
| Net Income | $-4,837 | $-7,280 | $-5,755 | $-8,611 | $-12,022 |
| EPS Basic Total Ops | -0.12 | -0.17 | -0.13 | -0.20 | -0.27 |
| EPS Basic Continuous Ops | -0.13 | -0.17 | -0.13 | -0.20 | -0.27 |
| EPS Basic Discontinuous Ops | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted Total Ops | -0.12 | -0.17 | -0.13 | -0.20 | -0.27 |
| EPS Diluted Continuous Ops | -0.13 | -0.17 | -0.13 | -0.20 | -0.27 |
| EPS Diluted Discontinuous Ops | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.17 | -0.13 | -0.20 | -0.28 |
| EBITDA(a) | $-5,303 | $-7,936 | $-7,750 | $-9,515 | $-13,310 |